Difference between revisions of "Anaplastic thyroid carcinoma"

From Libre Pathology
Jump to navigation Jump to search
(split out)
 
Line 4: Line 4:
Epidemiology:
Epidemiology:
*Very rare.
*Very rare.
*Horrible prognosis.
*Horrible prognosis - median survival of 8 months in one series.<ref name=pmid24554064>{{Cite journal  | last1 = Mohebati | first1 = A. | last2 = Dilorenzo | first2 = M. | last3 = Palmer | first3 = F. | last4 = Patel | first4 = SG. | last5 = Pfister | first5 = D. | last6 = Lee | first6 = N. | last7 = Tuttle | first7 = RM. | last8 = Shaha | first8 = AR. | last9 = Shah | first9 = JP. | title = Anaplastic thyroid carcinoma: a 25-year single-institution experience. | journal = Ann Surg Oncol | volume = 21 | issue = 5 | pages = 1665-70 | month = May | year = 2014 | doi = 10.1245/s10434-014-3545-5 | PMID = 24554064 }}</ref>
*Often presents with obstruction.
*Often presents with obstruction.
*Typically there is a history of a thyroid mass.
*Typically there is a history of a thyroid mass.

Latest revision as of 03:12, 4 March 2015

Anaplastic thyroid carcinoma is a rare aggressive tumour of the thyroid gland.

General

Epidemiology:

  • Very rare.
  • Horrible prognosis - median survival of 8 months in one series.[1]
  • Often presents with obstruction.
  • Typically there is a history of a thyroid mass.

Microscopic

Features:

Notes:

  • May have features of other thyroid carcinomas, e.g. psammoma bodies, papillae, nuclear changes of PTC.

DDx:

Images

IHC

  • Keratin (AE1/AE3) +ve.
  • Vimentin +ve, >90%.[2]
  • Thyroglobulin - rarely +ve (~15%).[2]
  • CEA -ve, calcitonin -ve; to r/o medullary.
  • p53 +ve.
  • TTF-1 +ve.

See also

References

  1. Mohebati, A.; Dilorenzo, M.; Palmer, F.; Patel, SG.; Pfister, D.; Lee, N.; Tuttle, RM.; Shaha, AR. et al. (May 2014). "Anaplastic thyroid carcinoma: a 25-year single-institution experience.". Ann Surg Oncol 21 (5): 1665-70. doi:10.1245/s10434-014-3545-5. PMID 24554064.
  2. 2.0 2.1 Ordóñez NG, El-Naggar AK, Hickey RC, Samaan NA (July 1991). "Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases". Am. J. Clin. Pathol. 96 (1): 15–24. PMID 1712540.